In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.